Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
George Fromm(United Therapeutics (United States)), Taylor H. Schreiber(Nantucket Cottage Hospital)
Cited by 49
Related Papers
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
|Cancer Cell|2024|177
Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation
|Journal of Clinical Investigation|2010|158